Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures in the life sciences sector [2] - The company provides high-quality products and solutions for industries such as biomedicine, healthcare, food and beverage, and environmental protection [2] Financial Performance - For Q1 2025, the company reported revenue of 66.94 million yuan, a year-on-year decrease of 16.33% [2] - The net profit for the same period was 3.53 million yuan, down 39.93% year-on-year, with a sales gross margin of 49.27% [2] Market Position - As of July 22, the company's stock closed at 22.8 yuan, with a rolling price-to-earnings (PE) ratio of 258.12, marking a new low in 163 days [1] - The average PE ratio in the medical device industry is 53.47, with a median of 37.00, placing Tailin Biological at the 117th position in the industry ranking [1][3] Shareholding Structure - As of Q1 2025, there is one institutional holder of Tailin Biological, which is a fund holding 511,200 shares valued at 1.1 million yuan [1]

Group 1 - The core viewpoint of the news highlights that TaiLin Bio's stock price closed at 19.04 yuan, down 2.91%, with a rolling PE ratio of 215.55 times, and a total market value of 2.308 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 48.08 times, with a median of 36.05 times, placing TaiLin Bio at the 117th position in the industry ranking [1][3] - The net inflow of main funds for TaiLin Bio on June 19 was 79,200 yuan, but over the past five days, there was a total outflow of 8.7005 million yuan [1] Group 2 - TaiLin Bio specializes in the research, production, and promotion of products related to microbiological testing and pollution control in the life sciences sector, providing high-quality solutions for various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 66.939 million yuan, a year-on-year decrease of 16.33%, and a net profit of 3.5282 million yuan, down 39.93%, with a sales gross margin of 49.27% [2]

5月19日，泰林生物今日收盘19.1元，上涨3.52%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到216.23倍，创29天以来新低，总市值23.15亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.26倍，行业中值36.71倍，泰林生物排 名第117位。 浙江泰林生物技术股份有限公司的主营业务是生命科学领域微生物检测与污染控制、创新药物研发生 产、过程分析和阻遏防护等产品的研发、生产和推广应用，为生物医药、医疗保健、食品饮料、环境保 护等行业提供具有高质量的产品和解决方案。公司的主要产品是集菌仪、集菌培养器、微生物检验仪、 微孔滤膜、酶底物法大肠菌群检测系统、酶底物智能培养计数系统、全自动两虫检测系统、生物指示 剂、生物指示剂抗力仪、质控菌株、隔离器、无菌传递舱、阻遏隔离器、多功能细胞处理工作站、蜂巢 培养系统（转运车+蜂巢培养箱）、无菌分装工作站、汽化过氧化氢发生器、过氧化氢雾化消毒机、全 自动菌落计数工作站、全自动无菌检查培养系统、细菌侵入测试仪、TOC分析仪、固体燃烧装置、生物 降解测试系统、真空/压力衰减测试仪、顶空氧分析仪、过滤器完整性测试仪、过氧化氢气体浓度分析 ...